and indicate that, by using standardized approaches for tissue antigen expression, evaluation and cutoff determination, single potentially useful prognostic markers could be identified.
classical prognostic parameters [10] [11] [12] [13] . Studies on combinations of different markers that might enhance the predictive power, including p53 together with p16, CCND1 and CCNE together with phosphorylated retinoblastoma protein as well as p21 and p27, suggest multiple alterations, especially in invasive UC that might contribute to recurrence, progression and, finally, worse survival [3] [4] [5] 14] . The expression of the antiapoptotic protein Bcl-2 and the proliferation index, assessed by Ki-67 and PCNA, have been reported to be potentially useful in predicting prognosis as well [4, 5, 7, 12, [14] [15] [16] [17] . Nevertheless, results obtained in different studies remain controversial.
To further assess the prognostic value of these multiple markers in UC and rationally address determination of prognostic cutoff levels applying receiver operator characteristics (ROC)-based methods, a large-scale immunohistochemical study on 99 specimens of patients with UC of the bladder in a tissue microarray (TMA) format was performed.
Material and Methods

Samples
Ninety-nine primary diagnoses of UC of the bladder, obtained by means of transurethral resection and diagnosed between January 1994 and December 1997 at the Institute of Pathology, Medical University of Innsbruck, were included in our study. All cases were reviewed by 2 pathologists (A.B. and G.M.) and reclassified according to the WHO 2004 classification. Our study group consisted of 27 pTa (22 low-grade and 5 high-grade UCs), 33 pT1 (2 low-grade and 32 high-grade UCs), 34 pT2-4 tumors (all highgrade UCs) and 5 carcinomata in situ (CIS). The clinical and pathological characteristics of the 99 patients have been reported elsewhere [18] .
TMA Construction
Samples were brought into a TMA format as previously described [19] . Three tissue cores (0.6 mm) and, in small specimens, 1-3 cores were obtained based on tissue amount including superficial, invasive portion tumor and the adjacent stroma.
Immunohistochemistry
Immunohistochemistry was performed, except for CCNE and p21, which were manually incubated, on an automated immunostainer (Nexes; Ventana), applying the streptavidin-biotin peroxidase technique with diaminobenzidine as chromogen. The antibodies, sources, dilutions, pretreatment and staining patterns are summarized in table 1 . Immunohistochemical staining was evaluated calculating the mean value of the relative proportion (percentage) of positively staining cells of the individual cores of each case based on at least 100 cells/case. For p16 and p27 cytoplasmic staining was also considered as previously reported [20, 21] .
Statistics
The Statistical Package of Social Sciences (SPSS 12.0 for Windows) was used. The Spearman rank test was used to test correlations between individual markers. The analysis of variance (ANOVA) was used to compare means between groups. For de- 
Results
TMA Quality
Three tissue cores/case could be arrayed in 90 cases, whereas 2 and 1 core could be obtained in 6 and 3 cases, respectively, resulting in a total number of 285 cores. After immunohistochemistry, between 225 (79%) and 262 (92%) cores and between 89 (90%) and 94 (95%) cases could be evaluated.
Expression and Correlations
The number of evaluable cases, the number of positive cases and the mean percentage 8 SD of positively staining cells, as well as the cutoffs for OS and RFS are summarized in table 2 . Nuclear and cytoplasmic expression of p16 was found in all positively staining specimens, while p27 expression was mainly restricted to the nuclei with only 6 specimens exhibiting additional cytoplasmic staining ( fig. 1) Receiver Operator Characteristics ROC showed significant discriminatory power considering OS for the expression of CCND1, with an optimal cutoff value of 0.15% ( table 4 ) . For all other markers, ROC curves showed only borderline significance or lacked discriminatory power considering OS ( table 4 ) . ROC showed borderline discriminatory significance for RFS for PCNA, CCNE, Bcl-2, p16 and p27, but lacked significant discriminatory power for all other markers ( table 4 ). Cutoff values for all markers considering OS and RFS determined by ROC/Y and used for Kaplan-Meier analysis are shown in table 2 .
Overall Survival OS was influenced by age, grade, stage and number of recurrences, but not by tumor-associated CIS and progressive disease [18] . A worse OS was found for Ki-67, p53 and p27 expression above the cutoff ( table 4 ; fig. 2 a) . Stratified by grade, p27 and Ki-67 expression above the cutoff, but not p53, were associated with a worse OS in high-grade tumors (p log rank = 0.028 and p log rank = 0.036, respectively). Stratified by stage, this finding held true for p27 expression in pTa and pT1 tumors (p log rank = 0.039 and p log rank = 0.014, respectively; fig. 2 b-d) . In addition, p16 expression in 1 1.5% of tumor cells showed an association with a better OS in low-grade (mean OS 103 months, median survival was not reached) and pTa tumors (mean OS 109 months, median survival was not reached) compared to p16 expression in ! 1.5% of tumor cells (mean OS 63 months, median OS 72 months and mean OS 73 months, median OS 84 months, respectively; p = 0.043 and p = 0.019, respectively; fig. 3 a, b) .
Multivariate analysis for OS considering age, grade, stage, number of recurrences, Ki-67, p53, p27 and p16 revealed that only increased age (relative risk = 1.062, 95% CI 1.108-1.018, p = 0.005), low number of recurrences (relative risk = 0.682, 95% CI 0.499-0.933, p = 0.017) and p53 expression in 1 14% (relative risk = 1.026, 95% CI 1.008-1.044, p = 0.004) were independent predictors of a worse OS.
Recurrence-Free Survival
Ki-67 expression in 1 8.75% of tumor cells was associated with a shorter RFS when compared to tumors with Ki-67 expression in ! 8.75%. Patients with PCNA expression of more than 74% had a longer RFS than those with PCNA expression below 74%. Similarly, Bcl-2, CCNE and p16 expression above the cutoff was associated with a better RFS ( table 4 ) . Considering all other known clinical and morphological parameters, only progress at relapse was associated with a worse RFS [18] .
Stratified by grade and stage, PCNA expression above the cutoff was associated with a longer RFS only in highgrade tumors (p log rank = 0.023). CCNE expression above the cutoff was only associated with a better RFS in highgrade (p log rank = 0.02), pTa (p log rank = 0.043) and pT1 tumors (p log rank = 0.008). Expression of p16 above the cutoff predicted a longer RFS in high-grade (p log rank = 0.011) and pT2-4 tumors (p log rank = 0.024; fig. 3 c, d ). Bcl-2 expression above the cutoff was a predictor for a better RFS in low-grade (p log rank = 0.0005) and pTa tumors (p log rank = 0.0001). Ki-67 did not show any association with RFS when either stratified for grade or stage.
Multivariate analysis for RFS considering progressive disease, Ki-67, PCNA, CCNE, p16 and Bcl-2 showed that only lacking progressive disease (relative risk = 0.234, 95% CI 0.109-0.503, p ! 0.001), Bcl-2 (relative risk = 0.978, 95% CI 0.958-0.998, p = 0.032) and CCNE expression (relative risk = 0.983, 95% CI 0.966-0.999, p = 0.04) were independent prognostic factors considering better RFS.
Discussion
In UC a variety of studies have investigated cell cycle markers for their predictive value concerning diseasefree, overall and disease-specific survival, but results often remained contradictory [2, 10] . Possible reasons include the heterogeneity of evaluated cases in different studies. Another important point is the use of different cutoffs for marker positivity, with only few studies determining the optimal cutoff values by ROC, rather than by stepwise analysis or by median or mean percentages of positively staining cells [6, 7, 12] . Similarly to previous studies, increased expression of Ki-67 and p53 proved to be associated with a worse OS in our collective [4, 12, [15] [16] [17] . Indeed, p53 mutations have been suggested as a key event in the development of aggressive UC phenotype [23] .
A particular new aspect of our study concerns the prognostic value of p16 and p27 protein expression. p16 was assessed as nuclear and cytoplasmic staining, as previously reported, though some authors regard cytoplasmic staining for p16 as nonspecific [20] . Nuclear expression of p16 above the cutoff values was associated with a better OS in low-grade and low-stage tumors and predicted a better RFS in high-grade and high-stage tumors in our patient cohort. Hitchings et al. [20] and Korkolopoulou et al. [24] , who studied the influence of p16 on disease survival and progression, emphasized the protective effect of p16 in UC, especially in tumors without p53 accumulation and normal expression of p16, which is in accordance with our finding of improved OS in lowgrade and pTa tumors, believed to lack p53 mutations [23] . Indeed, p16 promotor hypermethylations resulting in inactivation are more frequently observed in invasive than noninvasive tumors, indicating that inactivation of p16 is associated with a more aggressive phenotype, but the reported hypermethylation frequencies in UC of the bladder vary considerably [9, 25] . Additionally, lost p16 expression could also be due to deletions at 9p21, which are commonly observed in UC, but such deletions are as frequent or even more frequent in pTa and low-grade tumors compared to high-grade tumors [9, 26, 27] . Thus, retained p16 expression in UC, as observed in our cohort, may identify a distinct subgroup of both low-and highgrade as well as low-and high-stage UC patients without p16 gene alterations, which are probably accompanied by a better prognosis. Strong cytoplasmic p16 staining was often seen in high-grade tumors (all with accompanying nuclear staining), pointing towards a probable deregulation leading to cytoplasmic retention of p16, analogously to p27 [21] . Nevertheless, in our study RFS was better in these patients as well and one may speculate that cytoplasmic p16 accumulation could simply reflect a compensatory mechanism to overcome other defects in cell cycle regulation. We observed a negative correlation between p16 and CCND1 expression. Loss of p16 and high CCND1 has been shown to be associated with hyperphosphorylated retinoblastoma protein, resulting in increased cell proliferation [8] . Intact p16 could probably counterbalance the oncogenic potential of CCND1 in UC [2, 4, 8] . Interestingly in that consideration, we observed a tendency towards better OS for patients with CCND1 expression and several authors have linked CCND1 expression to low grade, low stage and better OS, too [2, 5] . It seems likely that the proposed oncogenic role of CCND1 can be modified, particularly in UC, by alterations in other cell cycle-controlling molecules, such as loss of p16 or p53 mutations. Such complex interactions may probably be responsible for the observed association of CCND1 expression with subsequent UC progression despite its potential positive prognostic importance considering OS [4, 6] .
Loss of p27 in bladder cancer has been reported to indicate a worse prognosis in UC [28] . In contrast, we showed that p27 expression in 1 5.5% of tumor cells is associated with worse OS in high-grade and pTa/pT1 tumors. Expression of p27 has been reported to be associated with an adverse disease outcome in diffuse large B cell lymphomas and posttranslational modifications were found to be responsible for the loss of the growthinhibitory function of p27 despite its cellular accumulation [21, 29] . Increased p27 expression in superficial highgrade tumors may probably represent accumulation of a nonfunctional protein, which is supported by the pres-ence of cytoplasmic p27 staining in some cases in our study. The impact of p27 on prognosis only in high-grade pTa/pT1 UCs further underlines differences between superficial low-and high-grade tumors. In addition, we observed a correlation of p27 and CCNE expression. Loss of p27 expression has been reported to be associated with loss of CCNE expression and a more aggressive tumor phenotype [3, 28, 30] . Indeed, high CCNE expression has been linked to a longer disease-specific survival and a lower risk of recurrence in UC [3, 30] . In our study, a better RFS in tumors with CCNE expression above the cutoff could be found, but no prognostic significance of CCNE concerning OS. On the other hand, gains of the CCNE gene have been detected in high-grade tumors, suggesting CCNE as a potential oncogene [30] . This finding is supported by several studies in other cancer types [31] [32] [33] [34] [35] . Therefore, we speculate that the impact of CCNE on prognosis probably depends on its expression causes (gene amplification, degradation failure, supraordinal cascades) and the functional state of p27 or other cell cycle regulatory molecules, including p53 and p21.
The prognostic value of other cell cycle-related proteins remains contradictory. Bcl-2, though associated with a better RFS, correlated with p53 accumulation, strongly suggesting complex interactions, which are reflected in the conflicting results on its prognostic impact obtained in different studies [14, 36, 37] . PCNA, though associated with Ki-67 expression, predicted a better RFS in high-grade tumors, which may be due to the interaction with other molecules, such as p21, modulating its functional activity [38] .
To summarize, our results based on standardized analysis approaches suggest complex partially redundant, partially concurrent interactions between the proteins involved in cell cycle control, proliferation and apoptosis in UC and point towards the role of p16-and p27-associated pathways. However, profound changes in complementary or concurrent complex cell cycle control pathways probably result in different impacts of single molecules on disease outcome. Therefore, though studies on the expression of cell cycle markers may result in new insights of their function, the use of these molecules as prognostic markers still needs to be particularly prospectively evaluated.
